Chromosome 8p-engineering and CRISPR-Cas9 viability screening reveal increased metastatic capacity of liver cancer cells targetable by patient-specific synthetic lethality [Cas9]

Accession: GSE220312
Source / host: GEO — NCBI GEO FTP
Disease relevance: MASLD / NAFLD / NASH (category: Functional-genomics, subtype: CRISPR/RNAi screen)
Modality / assay: crispr-screen
Platform: Expression profiling by high throughput sequencing, GPL23227
Organism: human
Samples: 12
Size (indexed): 7.7 MB (8040286 bytes)
Downloaded bytes: 7.7 MB (8040286 bytes)
Access / raw: public / OPEN-raw

Download

Files

FileSizeSHA256
GSE220312_RAW.tar7.7 MBc9c68c22adc44629…
filelist.txt1.8 KB36f0f59b7fbba88c…

Index note: 2 file(s); GSE220312_RAW.tar

Crawled by masld-atlas-crawler v1.0 at 2026-08-02T19:11:04Z.

About this dataset

This Expression profiling by high throughput sequencing, GPL23227 dataset provides single-cell gene expression from human liver samples, with disease state recorded as MASLD/NAFLD/NASH. It profiles about 12 cells or nuclei.

Analyze it in Drylab

Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:

  1. Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
  2. Normalize, select variable genes, then cluster the cells and draw a UMAP.
  3. Annotate clusters with marker genes and compare the cell-type mix between conditions.
  4. Run differential expression between cell types or samples to characterize masld/nafld/nash biology.